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Background:  Oxidation-specific epitopes (OSE) are immunogenic, pro-inflammatory and pro-atherogenic. The long-term predictive value of OSE 
biomarkers for CVD events is not known.
Methods: Oxidized phospholipids on apo B100 (OxPL/apoB), IgG and IgM autoantibodies to malondialdehyde-modified and copper-oxidized 
LDL (Cu-OxLDL) and apoB-immune complexes (apoB-IC) were measured in 765 subjects in 1995 and 656 subjects in 2000 in the Bruneck study, 
representing 45-84 year-old, previously healthy men and women from the general community.
Results: Over 15 years of follow-up from 1995-2010, 138 subjects reached the primary endpoint of incident CVD (ischemic stroke, myocardial 
infarction, new-onset unstable angina, acute coronary interventions and vascular death). OxPL/apoB levels were higher and IgM Cu-OxLDL and 
IgM apoB-IC lower in subjects with CVD events compared those without events. In a multivariable Cox model of 13 variables, the highest tertile of 
OxPL had a hazard ratio (HR) 95% confidence interval (95% CI) of 2.4 (1.5-3.7) for the combined CVD endpoint and 3.6 (1.8-7.4)] for the stroke 
endpoint compared to the lowest tertile. IgM Cu-OxLDL [HR 0.77 (0.62-0.97) for 1-SD)] and IgM MDA-LDL [HR 0.79 (0.66-0.95) for 1-SD)] were 
associated with lower risk of overall CVD, including stroke. Using OxPL/apoB, Cu-OxLDL IgG and MDA IgM variables, the area under the curve (AUC) 
increased from 0.664 [0.629-0.697] to 0.705 [0.672-0.737], P=0.048. The net reclassification index (NRI) was 0.163 (P= 0.0044) in subjects with 
incident CVD (n=138), 35 were correctly reclassified to a higher risk category and 18 were reclassified to a lower category. In subjects who remain 
free of CVD (n=627) 108 were correctly reclassified to a lower risk category and 83 were reclassified to a higher category. In subjects at intermediate 
risk (n=305) the NRI was 0.332 (P<0.0001).
Conclusion: OSE biomarkers predict 15-year CVD outcomes. Elevated baseline levels of OxPL/apoB levels predict increased risk of incident CVD, 
including stroke, whereas IgM autoantibodies predict lower risk. OSE biomarkers may provide clinical utility in addition to traditional risk factors by 
reclassifying subjects into higher or lower risk categories.
